Citric Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Citric Acid: From Pharmaceutical Excipient to Stomach Disease
One-Sentence Summary
Citric acid is a naturally occurring organic acid primarily used as a pharmaceutical excipient, food acidity regulator, and diagnostic test meal component, with no currently approved standalone therapeutic indications. The TxGNN model predicts it may be relevant to Stomach Disease with a score of 99.74%, supported by metabolomics observations and preclinical data, though no direct clinical intervention evidence currently exists.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved therapeutic indication (used as pharmaceutical excipient / food acidity regulator) |
| Predicted New Indication | Stomach Disease |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for citric acid as a standalone therapeutic agent. Based on known information, citric acid is a naturally occurring tricarboxylic acid that serves as a fundamental intermediate in the TCA (tricarboxylic acid / Krebs) cycle and is a well-documented normal component of human gastric juice (PMID 6027230). Its deep integration into gastric physiology provides the likely basis for the TxGNN model's prediction.
Citric acid's most established role in gastroenterology is as a diagnostic adjunct rather than a therapeutic agent: it is used as the test meal medium in the ¹³C-urea breath test (¹³C-UBT), where its acidic properties delay gastric emptying and measurably improve the accuracy of Helicobacter pylori detection in Asian populations (PMID 31505905). Separately, a preclinical study found that MX1 — a novel compound combining the H₂-blocker roxatidine with a bismuth-citric acid complex — demonstrated gastroprotective effects against stress-induced ulcers in rats (PMID 9379358), suggesting that citrate-containing compounds may interact with gastric mucosal defense mechanisms.
Metabolomics research adds further indirect support: serum citric acid levels are elevated prior to gastric cancer onset and correlate negatively with alkaline phosphatase in Korean cohorts (PMID 35900644), while TCA cycle upregulation — with citric acid as its central molecule — defines the MSC1 gastric cancer subtype associated with better prognosis (PMID 38959111). H. pylori infection also demonstrably alters TCA cycle metabolites in stomach tissue (PMID 28546118). These findings collectively indicate that the TxGNN prediction captures citric acid's physiological centrality in gastric biology, but current evidence remains observational and mechanistic rather than therapeutic.
Clinical Trial Evidence
No clinical trials directly investigate citric acid as a standalone treatment for stomach disease. The trials retrieved for this indication are largely studies of other interventions in related gastric conditions. The most thematically relevant are listed below:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07122284 | N/A | Completed | 42 | Metagenomic and metabolomic characterization of gut ecosystem in concurrent H. pylori infection and SIBO; citric acid may appear as a metabolic biomarker but is not the investigational drug |
| NCT03812380 | Phase 3 | Terminated | 62 | Effervescent calcium magnesium citrate to prevent PPI-related complications (fractures, hypomagnesaemia, CKD) in patients treated for gastric ulcer/gastritis; uses a citrate-containing compound but was terminated early |
| NCT05753306 | Phase 2 | Recruiting | 40 | Robotic cytoreduction and HIPEC for gastric cancer with limited peritoneal metastasis; stomach-related context but does not involve citric acid |
| NCT04350346 | N/A | Unknown | 70 | Motilitone vs Gasmotin for functional dyspepsia in gallstone patients; stomach-related but does not involve citric acid |
| NCT03320538 | N/A | Completed | 360 | Hou Gu Mi Xi (TCM) for peptic ulcer disease; stomach-related but does not involve citric acid |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31505905 | 2019 | Clinical Study | Gut and Liver | Citric acid test meal improves ¹³C-UBT diagnostic accuracy for H. pylori detection in Asian populations; establishes an active gastric role |
| 9379358 | 1997 | Preclinical | J Pharmacy & Pharmacology | MX1 (roxatidine + bismuth-citric acid complex) demonstrates gastroprotective efficacy against stress-induced ulcers in rats — the only preclinical evidence directly linking a citrate compound to gastric mucosal protection |
| 6027230 | 1967 | Basic Science | Gastroenterology | Citric acid confirmed as a normal constituent of human gastric juice; provides physiological baseline |
| 35900644 | 2022 | Observational | Metabolomics | High serum citric acid and L-carnitine levels negatively correlated with alkaline phosphatase; detectable before gastric cancer onset in Korean cohort — potential early-detection biomarker |
| 38959111 | 2024 | Molecular Classification | Cell Reports | TCA cycle upregulation (citric acid as central intermediate) defines the MSC1 gastric cancer subtype, which exhibits better prognosis and distinct TP53/RHOA mutations |
| 28546118 | 2017 | Preclinical | Microbial Pathogenesis | H. pylori infection progressively alters TCA cycle metabolites, including citric acid, in mouse gastric tissue over 1–6 months |
| 37477784 | 2024 | Review | Clinical & Translational Oncology | TCA cycle and mitochondrial energy metabolism reviewed as emerging therapeutic targets in gastric cancer; positions citric acid metabolism as pharmacologically relevant |
| 26088916 | 2015 | Metabolomics | Applied Biochemistry & Biotechnology | LC/MS metabolomic profiling of gastric cancer identifies dysregulation of citric acid–associated metabolic pathways as disease biomarkers |
| 9604442 | 1998 | Clinical Review | British Medical Bulletin | Overview of ¹³C-UBT (citric acid-assisted) for H. pylori diagnosis and monitoring of eradication therapy response |
| 2072799 | 1991 | Review | Medical Clinics of North America | Diet and nutrition in peptic ulcer disease; discusses how acidic components, including citric acid, may influence gastric acid secretion and mucosal irritation |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for citric acid in stomach disease is currently at Level L4 (preclinical data and metabolomics observations only), with no clinical trials directly testing citric acid as a standalone therapeutic intervention. The TxGNN model's high-confidence prediction likely captures citric acid's fundamental role in gastric physiology and the TCA cycle rather than an actionable therapeutic mechanism. Until a specific and testable clinical hypothesis is established, advancing this candidate is premature.
To proceed, the following is needed:
- Define a specific therapeutic hypothesis (e.g., TCA cycle modulation in gastric cancer metabolic reprogramming, H. pylori microenvironment acidification as anti-infective strategy, or gastric mucosal cytoprotection via bismuth-citrate complex formulation)
- Retrieve full mechanism of action data from DrugBank and TFDA/HSA package inserts (currently unavailable — Data Gap DG002)
- Conduct dedicated preclinical studies testing citric acid or citrate-containing compounds directly as a gastric disease treatment
- Determine a clinically appropriate formulation, dose, and route of administration distinct from its excipient/diagnostic role
- Resolve the safety data gap (Data Gap DG001): obtain TFDA package insert warnings and contraindications before any S1 safety assessment can proceed
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.